Liangzhi Xie

ORCID

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 13

Top Venues

Vaccines

Nature communications

Signal transduction and targeted therapy

Nature medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Jihai Tang, Qinghua Xu, Chaoyin Zhu, Kun Xuan, Tao Li, Qingru Li, Xingya Pang, Zhenqiu Zha, Jinwei Li, Liyang Qiao, Haiyang Xu, Gang Wu, Yan Tian, Jun Han, Cuige Gao, Jiang Yi, Gui Qian, Xuxin Tian, Liangzhi Xie
Immunogenicity of Tetravalent Protein Vaccine SCTV01E-2 against SARS-CoV-2 EG.5 Subvaraint: A Phase 2 Trial. Vaccines 12 (2) (2024)
Yuankai Shi, Wei Guo, Wei Wang, Yunteng Wu, Meiyu Fang, Xiaoming Huang, Ping Han, Qingyuan Zhang, Pin Dong, Xiaohong Zhou, Hanwei Peng, Chunhong Hu, Xiaopin Chen, Shurong Zhang, Zhiwei Chang, Xiaojiang Li, Yuhai Ding, Song Qu, Shanghua Jing, Songnan Zhang, Lin Gui, Yan Sun, Lin Wang, Yanyan Liu, Hui Wu, Guoqing Li, Zhichao Fu, Jianhua Shi, Hao Jiang, Yuansong Bai, Jiuwei Cui, Yulong Zheng, Wei Cui, Xiaojing Jia, Limin Zhai, Qing-Qing Cai, Deming Xiong, Yunong Wu, Junning Cao, Rong Wu, Guangyuan Hu, Liang Peng, Liangzhi Xie, Wenlin Gai, Yan Wang, Yuehua Su
Finotonlimab with chemotherapy in recurrent or metastatic head and neck cancer: a randomized phase 3 trial. Nature medicine (2024)
Gui Qian, Cuige Gao, Miaomiao Zhang, Yuanxin Chen, Liangzhi Xie
A Review of Protein-Based COVID-19 Vaccines: From Monovalent to Multivalent Formulations. Vaccines 12 (6) (2024)
Suad Hannawi, Linda Saf Eldin, Alaa Abuquta, Ahmad Alamadi, Sally A Mahmoud, Aala Hassan, Shuping Xu, Jian Li, Dongfang Liu, Adam Abdul Hakeem Baidoo, Dima Ibrahim, Mojtaba Alhaj, Yuanxin Chen, Qiang Zhou, Liangzhi Xie
Author Correction: Safety and immunogenicity of a tetravalent and bivalent SARS-CoV-2 protein booster vaccine in men. Nature communications 15 (1) (2024)
Jihai Tang, Qinghua Xu, Chaoyin Zhu, Kun Xuan, Tao Li, Qingru Li, Xingya Pang, Zhenqiu Zha, Jinwei Li, Liyang Qiao, Haiyang Xu, Gang Wu, Yan Tian, Jun Han, Cuige Gao, Jiang Yi, Gui Qian, Xuxin Tian, Liangzhi Xie
Immunogenicity of Tetravalent Protein Vaccine SCTV01E-2 against SARS-CoV-2 EG.5 Subvaraint: A Phase 2 Trial. Vaccines 12 (2) (2024)
Gui Qian, Cuige Gao, Miaomiao Zhang, Yuanxin Chen, Liangzhi Xie
A Review of Protein-Based COVID-19 Vaccines: From Monovalent to Multivalent Formulations. Vaccines 12 (6) (2024)
Suad Hannawi, Linda Saf Eldin, Alaa Abuquta, Ahmad Alamadi, Sally A Mahmoud, Aala Hassan, Shuping Xu, Jian Li, Dongfang Liu, Adam Abdul Hakeem Baidoo, Dima Ibrahim, Mojtaba Alhaj, Yuanxin Chen, Qiang Zhou, Liangzhi Xie
Author Correction: Safety and immunogenicity of a tetravalent and bivalent SARS-CoV-2 protein booster vaccine in men. Nature communications 15 (1) (2024)
Ruizhi Zhang, Junshi Zhao, Xiaoping Zhu, Qinghu Guan, Shujun Liu, Meihong Li, Jianghua Gao, Jie Tan, Feng Cao, Beifang Gan, Bo Wu, Jin Bai, Youquan Liu, Gang Xie, Chi Liu, Wei Zhao, Lixin Yan, Shuping Xu, Gui Qian, Dongfang Liu, Jian Li, Wei Li, Xuxin Tian, Jinling Wang, Shanshan Wang, Dongyang Li, Jing Li, Yuhuan Jiao, Xuefeng Li, Yuanxin Chen, Yang Wang, Wenlin Gai, Qiang Zhou, Liangzhi Xie
Efficacy of the tetravalent protein COVID-19 vaccine, SCTV01E: a phase 3 double-blind, randomized, placebo-controlled trial. Nature communications 15 (1) (2024)
Ruizhi Zhang, Junshi Zhao, Xiaoping Zhu, Qinghu Guan, Shujun Liu, Meihong Li, Jianghua Gao, Jie Tan, Feng Cao, Beifang Gan, Bo Wu, Jin Bai, Youquan Liu, Gang Xie, Chi Liu, Wei Zhao, Lixin Yan, Shuping Xu, Gui Qian, Dongfang Liu, Jian Li, Wei Li, Xuxin Tian, Jinling Wang, Shanshan Wang, Dongyang Li, Jing Li, Yuhuan Jiao, Xuefeng Li, Yuanxin Chen, Yang Wang, Wenlin Gai, Qiang Zhou, Liangzhi Xie
Efficacy of the tetravalent protein COVID-19 vaccine, SCTV01E: a phase 3 double-blind, randomized, placebo-controlled trial. Nature communications 15 (1) (2024)
Gui Qian, Cuige Gao, Miaomiao Zhang, Yuanxin Chen, Liangzhi Xie
A Review of Protein-Based COVID-19 Vaccines: From Monovalent to Multivalent Formulations. Vaccines 12 (6) (2024)
Chunyun Sun, Huiyu Wang, Ji Yang, Desheng Kong, Yuning Chen, Haiyue Wang, Lingling Sun, Jianbo Lu, Min Teng, Liangzhi Xie
Mutation N856K in spike reduces fusogenicity and infectivity of Omicron BA.1. Signal transduction and targeted therapy 8 (1) (2023)
Chunyun Sun, Huiyu Wang, Ji Yang, Desheng Kong, Yuning Chen, Haiyue Wang, Lingling Sun, Jianbo Lu, Min Teng, Liangzhi Xie
Mutation N856K in spike reduces fusogenicity and infectivity of Omicron BA.1. Signal transduction and targeted therapy 8 (1) (2023)
Suad Hannawi, Linda Saf Eldin, Alaa Abuquta, Ahmad Alamadi, Sally A Mahmoud, Aala Hassan, Shuping Xu, Jian Li, Dongfang Liu, Adam Abdul Hakeem Baidoo, Dima Ibrahim, Mojtaba Alhaj, Yuanxin Chen, Qiang Zhou, Liangzhi Xie
Safety and immunogenicity of a tetravalent and bivalent SARS-CoV-2 protein booster vaccine in men. Nature communications 14 (1) (2023)

Liangzhi Xie.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Liangzhi Xie